OHSU in the news

The tech Biden needs to get federal workers vaccinated

POLITICO August 04, 2021
In a story about an increase in virtual intensive and emergency care during the pandemic, Marshall Lee, M.D., says patients appreciate the attention a virtual ICU offers when hospital staff are stretched thin.

Back to school this year includes physical, emotional prep

KOIN-TV August 03, 2021
In a story about in-person learning, Bonnie Nagel, Ph.D., says: “I feel like kids are pretty resilient. I don’t have major concerns for kids in terms of mask wearing or distancing. They sort of roll with this stuff.”

Targeting gene therapy for achromatopsia

Opthalmology Times August 02, 2021
Mark Pennesi, M.D., Ph.D., says preliminary results of Applied Genetic Technologies Corporation-sponsored clinical trials evaluating gene therapies for achromatopsia show encouraging signs of biologic activity.

Retired neurologist with Alzheimer’s knows firsthand the risks of Biogen’s new drug

The Boston Globe July 31, 2021
The Boston Globe features retired OHSU neurologist Daniel Gibbs, M.D., in a story about a new FDA-approved drug for Alzheimer’s disease. Gibbs, who has Alzheimer’s and experienced severe side effects while participating in a clinical trial for the drug in 2017, says: “I would argue that in the first year or so, administration of the drug should be limited to [providers] with experience with the drug, not just any guy with a shingle.”

The quest for rest: Sleep could be the key to fighting Alzheimer’s—and a huge business opportunity

Fortune July 31, 2021
Fortune magazine notes that Miranda Lim, M.D., Ph.D., is at the forefront of clinical care and research involving the importance of sleep in potentially staving off cognitive decline: “We used to think that sleep problems were just another symptom of Alzheimer’s. Our big discovery was that the lack of sleep involves brain processes that may develop into the disease.”
See more stories